April 1, 2019
Teva’s COPAXONE® 40mg – Favorable Response from European Patent Office
JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that a three-member panel of the European Patent Office’s…